A-620223 is a PARP-1 inhibitor with a K i of 8 nM against PARP-1 and EC 50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) ( HY-17364 ) and in an MX-1 breast xenograph model in combination with Cisplatin ( HY-17394 ). A-620223 can be used for the studies of melanoma and breast cancer .
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PARP
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.